Tomoya Kitani1,2,3, Sang-Ging Ong4, Chi Keung Lam1,2,3, June-Wha Rhee1,2,3, Joe Z Zhang1,2,3, Angelos Oikonomopoulos1,2,3, Ning Ma1,2,3, Lei Tian1,2,3, Jaecheol Lee5, Melinda L Telli6, Ronald M Witteles1,3, Arun Sharma7, Nazish Sayed1,2,3, Joseph C Wu1,2,8,3. 1. Stanford Cardiovascular Institute, CA (T.K., C.K.L., J.-W.R., J.Z.Z., A.O., N.M., L.T., R.M.W., N.S., J.C.W.). 2. Institute for Stem Cell Biology and Regenerative Medicine, Stanford, CA (T.K., C.K.L., J.-W.R., J.Z.Z., A.O., N.M., L.T., N.S., J.C.W.). 3. Department of Medicine, Division of Cardiology (T.K., C.K.L., J.-W.R., J.Z.Z., A.O., N.M., L.T., R.M.W., N.S., J.C.W.), Stanford University School of Medicine, CA. 4. Departments of Pharmacology and Medicine, University of Illinois College of Medicine, Chicago (S.-G.P). 5. School of Pharmacy, Sungkyunkwan University, Suwon, Korea (J.L.). 6. Division of Oncology (M.L.T.), Stanford University School of Medicine, CA. 7. Department of Genetics, Harvard Medical School, Boston, MA (A.S.). 8. Stanford Cancer Institute, CA (J.C.W.).
Abstract
BACKGROUND: Molecular targeted chemotherapies have been shown to significantly improve the outcomes of patients who have cancer, but they often cause cardiovascular side effects that limit their use and impair patients' quality of life. Cardiac dysfunction induced by these therapies, especially trastuzumab, shows a distinct cardiotoxic clinical phenotype in comparison to the cardiotoxicity induced by conventional chemotherapies. METHODS: We used the human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) platform to determine the underlying cellular mechanisms in trastuzumab-induced cardiac dysfunction. We assessed the effects of trastuzumab on structural and functional properties in iPSC-CMs from healthy individuals and performed RNA-sequencing to further examine the effect of trastuzumab on iPSC-CMs. We also generated human induced pluripotent stem cells from patients receiving trastuzumab and examined whether patients' phenotype could be recapitulated in vitro by using patient-specific iPSC-CMs. RESULTS: We found that clinically relevant doses of trastuzumab significantly impaired the contractile and calcium-handling properties of iPSC-CMs without inducing cardiomyocyte death or sarcomeric disorganization. RNA-sequencing and subsequent functional analysis revealed mitochondrial dysfunction and altered the cardiac energy metabolism pathway as primary causes of trastuzumab-induced cardiotoxic phenotype. Human iPSC-CMs generated from patients who received trastuzumab and experienced severe cardiac dysfunction were more vulnerable to trastuzumab treatment than iPSC-CMs generated from patients who did not experience cardiac dysfunction following trastuzumab therapy. It is important to note that metabolic modulation with AMP-activated protein kinase activators could avert the adverse effects induced by trastuzumab. CONCLUSIONS: Our results indicate that alterations in cellular metabolic pathways in cardiomyocytes could be a key mechanism underlying the development of cardiac dysfunction following trastuzumab therapy; therefore, targeting the altered metabolism may be a promising therapeutic approach for trastuzumab-induced cardiac dysfunction.
BACKGROUND: Molecular targeted chemotherapies have been shown to significantly improve the outcomes of patients who have cancer, but they often cause cardiovascular side effects that limit their use and impair patients' quality of life. Cardiac dysfunction induced by these therapies, especially trastuzumab, shows a distinct cardiotoxic clinical phenotype in comparison to the cardiotoxicity induced by conventional chemotherapies. METHODS: We used the human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) platform to determine the underlying cellular mechanisms in trastuzumab-induced cardiac dysfunction. We assessed the effects of trastuzumab on structural and functional properties in iPSC-CMs from healthy individuals and performed RNA-sequencing to further examine the effect of trastuzumab on iPSC-CMs. We also generated human induced pluripotent stem cells from patients receiving trastuzumab and examined whether patients' phenotype could be recapitulated in vitro by using patient-specific iPSC-CMs. RESULTS: We found that clinically relevant doses of trastuzumab significantly impaired the contractile and calcium-handling properties of iPSC-CMs without inducing cardiomyocyte death or sarcomeric disorganization. RNA-sequencing and subsequent functional analysis revealed mitochondrial dysfunction and altered the cardiac energy metabolism pathway as primary causes of trastuzumab-induced cardiotoxic phenotype. Human iPSC-CMs generated from patients who received trastuzumab and experienced severe cardiac dysfunction were more vulnerable to trastuzumab treatment than iPSC-CMs generated from patients who did not experience cardiac dysfunction following trastuzumab therapy. It is important to note that metabolic modulation with AMP-activated protein kinase activators could avert the adverse effects induced by trastuzumab. CONCLUSIONS: Our results indicate that alterations in cellular metabolic pathways in cardiomyocytes could be a key mechanism underlying the development of cardiac dysfunction following trastuzumab therapy; therefore, targeting the altered metabolism may be a promising therapeutic approach for trastuzumab-induced cardiac dysfunction.
Authors: Krishna K Singh; Praphulla C Shukla; Adrian Quan; Fina Lovren; Yi Pan; Jesse I Wolfstadt; Milan Gupta; Mohammed Al-Omran; Howard Leong-Poi; Hwee Teoh; Subodh Verma Journal: Biochem Biophys Res Commun Date: 2011-07-02 Impact factor: 3.575
Authors: Steven A Crone; You-Yang Zhao; Lian Fan; Yusu Gu; Susumu Minamisawa; Yang Liu; Kirk L Peterson; Ju Chen; Ronald Kahn; Gianluigi Condorelli; John Ross; Kenneth R Chien; Kuo-Fee Lee Journal: Nat Med Date: 2002-05 Impact factor: 53.440
Authors: Leo I Gordon; Michael A Burke; Amareshwar T K Singh; Sheila Prachand; Elliot D Lieberman; Lin Sun; Tejaswitha Jairaj Naik; Sathyamangla V Naga Prasad; Hossein Ardehali Journal: J Biol Chem Date: 2008-11-18 Impact factor: 5.157
Authors: Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge Journal: Circ Res Date: 2019-10-10 Impact factor: 17.367
Authors: Peiqiang Yi; Huan Li; Yuehua Fang; Jun Su; Cheng Xu; Lu Cao; Min Li; Jiayi Chen Journal: Am J Cancer Res Date: 2020-02-01 Impact factor: 6.166
Authors: Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu Journal: Circ Res Date: 2019-09-19 Impact factor: 17.367